Takeda Pharma Files June 2025 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-private-issuer, sec-filing, regulatory-update
TL;DR
Takeda filed its June 6-K, standard foreign issuer update.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on June 30, 2025, reporting information as a foreign private issuer for the month of June 2025. The filing is in accordance with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. Takeda is based in Tokyo, Japan, and its principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668.
Why It Matters
This filing provides routine updates for Takeda Pharmaceutical as a foreign private issuer, ensuring transparency for investors regarding its ongoing reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial results or significant corporate actions.
Key Players & Entities
- TAKEDA PHARMACEUTICAL CO LTD (company) — Filer
- 0001395064-25-000105 (accession_number) — Filing identifier
- 20250630 (date) — Filing date
- 001-38757 (sec_file_number) — SEC file number
- 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668 (address) — Principal executive offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information that the registrant may be required to disclose or make public in its home country.
When was this specific Form 6-K filed?
This Form 6-K was filed on June 30, 2025.
What is Takeda Pharmaceutical Company Limited's primary business classification?
Takeda Pharmaceutical Company Limited is classified under Standard Industrial Classification code 2834, which is Pharmaceutical Preparations.
Does Takeda file its annual reports on Form 20-F or 40-F?
Takeda indicates that it files its annual reports under cover of Form 20-F.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).